» Articles » PMID: 37388220

Chronic Obstructive Pulmonary Disease Alters the Genetic Landscape and Tumor Immune Microenvironment in Lung Cancer Patients

Overview
Journal Front Oncol
Specialty Oncology
Date 2023 Jun 30
PMID 37388220
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Chronic obstructive pulmonary disease (COPD) and lung cancer are leading causes of morbidity and mortality worldwide. Studies have reported molecular alterations in patients with lung cancer and in patients with COPD. However, few investigation has been conducted on the molecular characteristics of lung cancer patients with COPD.

Materials And Methods: We performed a retrospective cohort study that included 435 patients with pathologically confirmed lung cancer at the Ruijin Hospital. For patients with documented spirometry, Global Initiative for Chronic Obstructive Lung Disease criteria were used to define COPD. For patients without documented spirometry, chest computed tomography and other clinical information were used to define COPD. Tumor tissue DNA was extracted from formalin-fixed paraffin-embedded samples. DNA mutation analysis, multiplex immunohistochemistry (mIHC), calculation of tumor mutational burden (TMB), mutant-allele tumor heterogeneity (MATH), and predication of neoantigens were performed.

Results: Although SNV mutations in lung cancer patients with COPD (G1 group) were generally higher than those in lung cancer patients without COPD (G2 group), the difference in the number of mutations was insignificant between the two groups. Of the 35 mutated genes, the number of them was higher in G1 than in G2, except that of EGFR. PI3K-Akt signaling pathway was enriched from significantly different genes. While TMB and MATH levels were not significantly different, the tumor neoantigen burdenwas markedly higher in G1 than that in G2. The level of CD68+ macrophages was significant higher in the stroma and total areas in the G1 group than in G2 group. The level of CD8+ lymphocytes was markedly higher in the stroma and showed a clear tendency forhigher expression in the G1 group than inthe G2 group. No significant differences were observed for the level of programmed death-ligand 1+ (PD-L1+), programmed death 1+ (PD-1+), and CD68PD-L1 in the stroma, tumor and total areas.

Conclusion: Our study revealed different genetic aberrations and pathways, higher neoantigen burden, and higher level of CD68+ macrophages and CD8+ T lymphocytes in lung cancer patients with COPD. Our investigation implies that the existence of COPD should be considered and immunotherapy is a potential choice when treating lung cancer patients with COPD.

Citing Articles

COPD and Immune Checkpoint Inhibitors for Cancer: A Literature Review.

Lycan Jr T, Norton D, Ohar J Int J Chron Obstruct Pulmon Dis. 2024; 19:2689-2703.

PMID: 39677829 PMC: 11639883. DOI: 10.2147/COPD.S490252.


Down-regulated HHLA2 enhances neoadjuvant immunotherapy efficacy in patients with non-small cell lung cancer (NSCLC) with chronic obstructive pulmonary disease (COPD).

Zeng A, Yin Y, Xu Z, Abuduwayiti A, Yang F, Shaik M BMC Cancer. 2024; 24(1):396.

PMID: 38553708 PMC: 10979619. DOI: 10.1186/s12885-024-12137-5.

References
1.
Yi Y, Ban W, Sohng K . Effect of COPD on symptoms, quality of life and prognosis in patients with advanced non-small cell lung cancer. BMC Cancer. 2018; 18(1):1053. PMC: 6206922. DOI: 10.1186/s12885-018-4976-3. View

2.
Biton J, Ouakrim H, Dechartres A, Alifano M, Mansuet-Lupo A, Si H . Impaired Tumor-Infiltrating T Cells in Patients with Chronic Obstructive Pulmonary Disease Impact Lung Cancer Response to PD-1 Blockade. Am J Respir Crit Care Med. 2018; 198(7):928-940. DOI: 10.1164/rccm.201706-1110OC. View

3.
Shah S, Blanchette C, Coyle J, Kowalkowski M, Arthur S, Howden R . Survival associated with chronic obstructive pulmonary disease among SEER-Medicare beneficiaries with non-small-cell lung cancer. Int J Chron Obstruct Pulmon Dis. 2019; 14:893-903. PMC: 6503488. DOI: 10.2147/COPD.S185837. View

4.
Liu Y, Zugazagoitia J, Shabbir Ahmed F, Henick B, Gettinger S, Herbst R . Immune Cell PD-L1 Colocalizes with Macrophages and Is Associated with Outcome in PD-1 Pathway Blockade Therapy. Clin Cancer Res. 2019; 26(4):970-977. PMC: 7024671. DOI: 10.1158/1078-0432.CCR-19-1040. View

5.
Massion P, Taflan P, Shyr Y, Rahman S, Yildiz P, Shakthour B . Early involvement of the phosphatidylinositol 3-kinase/Akt pathway in lung cancer progression. Am J Respir Crit Care Med. 2004; 170(10):1088-94. DOI: 10.1164/rccm.200404-487OC. View